Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 28, 2018* Libtayo is the third anti-PD-1 approved in the U.S.
-
Sep 12, 2018* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
-
Sep 5, 2018Industry executive adds considerable financial expertise as audit committee chairperson
-
Sep 4, 2018
-
Sep 3, 2018- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder
-
Jul 31, 2018- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention
-
Jul 30, 2018Nearly 70 million doses to be manufactured this season